Replies to post #826409 on NorthWest Biotherapeutics Inc (NWBO)

[brazen22]

I think this may have drifted from the original claim. The original statement was that NWBO had identified an off site location already suitable for EDEN installation. That is what I was questioning.

If the point is only that NWBO may be exploring future CDMO capacity, I agree that is possible. The 10-Q says they are in “continued discussions” for a possible second DCVax production operation using an existing GMP facility.

But that is different from saying NWBO has an EDEN-ready off site manufacturing site. The 10-Q does not say EDEN, Flaskworks, site identified, contract signed, tech transfer started, validation underway, or MHRA pathway established.

In any case, I am trying to understand how much weight to give this alternate CDMO language. If it is material, the 10-Q gives very little detail: no site, no CDMO name, no contract, no tech transfer status, no validation status, and no MHRA pathway. If it is immaterial, then I do not see how it can be used to point to near term readiness or a serious parallel development track.

And under your own disclosure theory, this does not look like the kind of information that would move the stock in a sustained way. So what is the point of the disclosure in the first place? It looks more like trying to make a planning discussion sound like serious commercial buildout.

If the approval case rests on the artisan process, then near term expansion should mean more artisan capacity, not assuming an unapproved EDEN process can be dropped into a third party site. EDEN may be the future, but it is not a shortcut unless it has already been validated, accepted, and tied into the MAA.

CRL/Cognate history may make them a logical name to speculate about, but prior familiarity with L or Direct is not the same as current approved DCVax-L/EDEN commercial manufacturing readiness. At best, it might shorten the learning curve. It does not eliminate contracts, tech transfer, qualification, validation, QA/QC setup, release testing, chain of identity controls, MHRA acceptance, and the money to pay for it.

So if we are talking about future planning, fine. If we are talking about an EDEN ready alternate site, I still do not see that disclosed. Based on the 10-Q language, I see planning discussions, not an alternate manufacturing solution ready to support a near term ramp.

[beartrap12]

Excellent point, DocLogic. You said:

Sure but parallel ramp up makes more sense with a partnership in mind

Could Dr. Jenkins have brought along/convinced a BP to partner with NWBO? Could that be driving the decision to take on a second manufacturing location in the UK?
Of course, Linda has been working on future plans for DCVax for many years, so she may not have needed Dr. Jenkins help. But her new position with our company certainly didn't hurt.